8,508 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,508 shares of the medical research company’s stock, valued at approximately $478,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock valued at $211,104,000 after purchasing an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in Exact Sciences by 10.9% in the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after buying an additional 245,980 shares in the last quarter. Bellevue Group AG lifted its position in shares of Exact Sciences by 25.1% during the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after acquiring an additional 290,585 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Exact Sciences by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock worth $88,017,000 after acquiring an additional 45,015 shares during the period. Finally, Groupama Asset Managment purchased a new position in Exact Sciences in the 3rd quarter valued at approximately $821,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on EXAS. Canaccord Genuity Group decreased their target price on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. TD Cowen increased their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Citigroup dropped their target price on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group lowered their price target on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus cut their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Price Performance

EXAS opened at $50.59 on Friday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The company’s 50 day simple moving average is $56.42 and its 200 day simple moving average is $60.06. The stock has a market capitalization of $9.36 billion, a PE ratio of -43.24 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.